After a successful clinical trial, Pharmaceutical giant Eli Lilly seeks approval for its diabetes drug to get added to the U.S. weight loss market.
, a leading pharmaceutical company, revealed its plans to seek approval for Tirzepatide, a diabetes medication, to be added to the weight loss market in the U.S. The decision was based on a recent clinical trial that demonstrated encouraging results. Tirzepatide, currently authorized as Mounjaro for treating type 2 diabetes, is given via injection once a week.were involved in a 72-week clinical trial conducted by Eli Lilly. The participants who received the highest dosage lost 15.
The gastrointestinal hormone GLP-1 is imitated by Tirzepatide, which activates receptors in the brain responsible for appetite regulation. The GLP-1 analogs are widely regarded by experts as a breakthrough since they cause much greater weight loss compared to existing drugs. Tirzepatide, originally approved in May 2022 in the U.S. for diabetes treatment, is already being prescribed by some doctors for weight loss.
industry, with approximately 40% of Americans believed to be obese. Morgan Stanley predicts that the global market for obesity treatments may reach $54 billion by 2030.In the U.S., Novo Nordisk's Wegovy has already been approved by the Food and Drug Administration for weight loss and uses semaglutide, another GLP-1-mimicking drug.
There is concern among experts that some individuals who are not clearly overweight may use these drugs to shed a few pounds. Additionally, theare intended for long-term use, and there is a risk of regaining weight once treatment is discontinued. Eli Lilly's Tirzepatide drug may provide a novel treatment alternative for people battling obesity and type 2 diabetes. The company's application for approval is highly anticipated, and if approved, the drug could become a major contender in the weight loss industry. However, it is crucial to ensure that the drug is used properly and under medical supervision to attain sustainable weight loss outcomes in the long run.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Eli Lilly seeks FDA approval for diabetes drug to be used for weight lossPharmaceutical company Eli Lilly is pushing for FDA approval for Tirzepatide, a medication used to help control blood sugar for type-2 diabetics, to be used for another purpose: weight loss.
Lire la suite »
Obesity is a chronic disease. It's why treating it will be so profitable unless payers push backEli Lilly's earnings call on Thursday included a frank discussion of the chronic nature of weight loss treatment.
Lire la suite »
New Weight Loss Drug May Launch in US After Promising Clinical TrialPharmaceutical giant Eli Lilly said Thursday it will seek approval to add its diabetes drug to the buzzy US weight loss market after achieving promising results in a new clinical trial.
Lire la suite »
2023 NFL Draft: Best priority free agentsThe draft doesn't end after seven rounds. NFL teams fill out their rosters with priority free agents like Army's Andre Carter and Alabama's Eli Ricks
Lire la suite »
Presidential battleground states weigh more election fundingAhead of the 2024 presidential election, officials in several battleground states have proposed boosting funding to add staff, enhance security and expand training within election offices that are facing heavier workloads and heightened public scrutiny.
Lire la suite »
It’s not just soda: Nutritionists weigh in on the absolute worst drinks for your healthBefore you load up your grocery cart or place an order at the coffee shop, restaurant or bar, beware of additives and sugar that may be lurking in your favorite drinks.
Lire la suite »